Skip to content

Study · Case report or series · n = 1 · 2010

1 result

Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant.

Ricker JM, Foody WF, Shumway NM, Shaw JC

Southern medical journal1 Jan 2010Cited by 2 (Europe PMC)

PMID19996852 (opens in a new tab)DOI10.1097/smj.0b013e3181c376a6 (opens in a new tab)PepBankPUB-19996852
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A patient with advanced prostate cancer developed liver injury after receiving a histrelin (Vantus) implant.

    In plain wordsA patient with advanced prostate cancer developed liver injury after a histrelin implant.

    Peptide
    Histrelin
    Outcome
    Not applicableLiver injury
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.